JP2005518781A - 良性および悪性の結腸直腸腫瘍中で発現する分泌遺伝子および細胞表面遺伝子 - Google Patents
良性および悪性の結腸直腸腫瘍中で発現する分泌遺伝子および細胞表面遺伝子 Download PDFInfo
- Publication number
- JP2005518781A JP2005518781A JP2003526936A JP2003526936A JP2005518781A JP 2005518781 A JP2005518781 A JP 2005518781A JP 2003526936 A JP2003526936 A JP 2003526936A JP 2003526936 A JP2003526936 A JP 2003526936A JP 2005518781 A JP2005518781 A JP 2005518781A
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- subject
- amount
- renal dipeptidase
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 65
- 206010009944 Colon cancer Diseases 0.000 title claims description 76
- 210000004027 cell Anatomy 0.000 title abstract description 14
- 208000013489 benign neoplasm of large intestine Diseases 0.000 title description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 102000003850 Dipeptidase 1 Human genes 0.000 claims description 108
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 108
- 108020004999 messenger RNA Proteins 0.000 claims description 107
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 76
- 239000000758 substrate Substances 0.000 claims description 50
- 210000002540 macrophage Anatomy 0.000 claims description 44
- 102000004127 Cytokines Human genes 0.000 claims description 37
- 108090000695 Cytokines Proteins 0.000 claims description 37
- 230000002401 inhibitory effect Effects 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 30
- 239000008280 blood Substances 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 19
- 239000007795 chemical reaction product Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 230000002285 radioactive effect Effects 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 5
- 239000002872 contrast media Substances 0.000 claims description 4
- 210000000512 proximal kidney tubule Anatomy 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000002591 computed tomography Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 229940090955 Dipeptidase inhibitor Drugs 0.000 claims description 2
- 238000003499 nucleic acid array Methods 0.000 claims 4
- 150000008574 D-amino acids Chemical group 0.000 claims 2
- 230000014509 gene expression Effects 0.000 abstract description 41
- 208000003200 Adenoma Diseases 0.000 abstract description 27
- 238000003753 real-time PCR Methods 0.000 abstract description 19
- 206010001233 Adenoma benign Diseases 0.000 abstract description 16
- 238000007901 in situ hybridization Methods 0.000 abstract description 11
- 238000004458 analytical method Methods 0.000 abstract description 10
- 101100321720 Arabidopsis thaliana PP2AA1 gene Proteins 0.000 abstract description 9
- 210000001072 colon Anatomy 0.000 abstract description 8
- 210000000981 epithelium Anatomy 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 abstract 1
- 101000979288 Homo sapiens Negative elongation factor E Proteins 0.000 abstract 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 238000010222 PCR analysis Methods 0.000 abstract 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 abstract 1
- 238000012882 sequential analysis Methods 0.000 abstract 1
- 201000002758 colorectal adenoma Diseases 0.000 description 34
- 238000001514 detection method Methods 0.000 description 25
- 102100021466 Sarcoma antigen 1 Human genes 0.000 description 23
- 235000002020 sage Nutrition 0.000 description 23
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 239000003550 marker Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100033468 Lysozyme C Human genes 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 description 2
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 229940127422 Dipeptidase Inhibitors Drugs 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000836983 Homo sapiens Secretoglobin family 1D member 1 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000016997 Lithostathine Human genes 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 108050000633 Lysozyme C Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102100028659 Secretoglobin family 1D member 1 Human genes 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000002579 sigmoidoscopy Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Walking Sticks, Umbrellas, And Fans (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31749401P | 2001-09-07 | 2001-09-07 | |
| US38380502P | 2002-05-30 | 2002-05-30 | |
| PCT/US2002/028518 WO2003022863A1 (en) | 2001-09-07 | 2002-09-09 | Secreted and cell surface genes expressed in benign and malignant colorectal tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005518781A true JP2005518781A (ja) | 2005-06-30 |
| JP2005518781A5 JP2005518781A5 (enExample) | 2006-01-05 |
Family
ID=26980985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526936A Pending JP2005518781A (ja) | 2001-09-07 | 2002-09-09 | 良性および悪性の結腸直腸腫瘍中で発現する分泌遺伝子および細胞表面遺伝子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8029764B2 (enExample) |
| EP (1) | EP1430071B1 (enExample) |
| JP (1) | JP2005518781A (enExample) |
| AT (1) | ATE504594T1 (enExample) |
| DE (1) | DE60239690D1 (enExample) |
| WO (1) | WO2003022863A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004010846A2 (en) * | 2002-07-27 | 2004-02-05 | The Johns Hopkins School Of Medicine | Design and synthesis of renal dipeptidase inhibitors |
| WO2006066916A1 (en) * | 2004-12-23 | 2006-06-29 | Roche Diagnostics Gmbh | Use of microsomal dipeptidase as a marker for colorectal cancer |
| CN101305094A (zh) | 2005-09-30 | 2008-11-12 | 抗癌股份有限公司 | 鉴定人早期癌症、癌症发展和复发标志物的方法 |
| EP2544006A1 (en) * | 2007-06-04 | 2013-01-09 | Diagnoplex | Biomarker combinations for colorectal cancer |
| JP2013508415A (ja) | 2009-10-23 | 2013-03-07 | マンカインド コーポレイション | 癌の免疫療法、および治療の方法 |
| WO2015138879A1 (en) * | 2014-03-13 | 2015-09-17 | Massachusetts Institute Of Technology | Compositions containing pufa, uridine and choline and methods of use thereof |
| US20160209415A1 (en) * | 2015-01-20 | 2016-07-21 | Poochon Scientific LLC | Method to predict or diagnose a colorectal cancer |
| EP3281016A1 (en) | 2015-04-10 | 2018-02-14 | Applied Proteomics Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| CN105603093A (zh) * | 2016-02-05 | 2016-05-25 | 广州复能基因有限公司 | 以MIC-1 cDNA为模板制备RNA探针的方法 |
| CN109402125A (zh) * | 2018-12-11 | 2019-03-01 | 宁夏医科大学总医院 | 一种环状RNA hsa_circTGFBI_007及其特异性扩增引物和应用 |
| CN109402119A (zh) * | 2018-12-11 | 2019-03-01 | 宁夏医科大学总医院 | 一种环状RNA hsa_circTGFBI_001及其特异性扩增引物和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998053319A2 (en) * | 1997-05-21 | 1998-11-26 | The Johns Hopkins University | Gene expression profiles in normal and cancer cells |
-
2002
- 2002-09-09 US US10/487,934 patent/US8029764B2/en active Active
- 2002-09-09 EP EP02773302A patent/EP1430071B1/en not_active Expired - Lifetime
- 2002-09-09 DE DE60239690T patent/DE60239690D1/de not_active Expired - Lifetime
- 2002-09-09 WO PCT/US2002/028518 patent/WO2003022863A1/en not_active Ceased
- 2002-09-09 JP JP2003526936A patent/JP2005518781A/ja active Pending
- 2002-09-09 AT AT02773302T patent/ATE504594T1/de not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998053319A2 (en) * | 1997-05-21 | 1998-11-26 | The Johns Hopkins University | Gene expression profiles in normal and cancer cells |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60239690D1 (de) | 2011-05-19 |
| EP1430071A4 (en) | 2005-11-02 |
| EP1430071B1 (en) | 2011-04-06 |
| ATE504594T1 (de) | 2011-04-15 |
| US8029764B2 (en) | 2011-10-04 |
| WO2003022863A1 (en) | 2003-03-20 |
| US20040265824A1 (en) | 2004-12-30 |
| EP1430071A1 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230250437A1 (en) | Oligonucleotide probes and uses thereof | |
| US20220290124A1 (en) | Oligonucleotide probes and uses thereof | |
| KR20220111246A (ko) | 순환 뉴클레오솜을 단리하는 방법 | |
| CN112626207B (zh) | 一种用于区分非侵袭性和侵袭性无功能垂体腺瘤的基因组合 | |
| WO2014062845A1 (en) | Compositions and methods for detecting sessile serrated adenomas/polyps | |
| JP2005518781A (ja) | 良性および悪性の結腸直腸腫瘍中で発現する分泌遺伝子および細胞表面遺伝子 | |
| JP2002515591A (ja) | 結腸癌を診断し、モニターし、そして病期決定する新規方法 | |
| JP4353799B2 (ja) | 転移に関連するホスファターゼ | |
| JP2800850B2 (ja) | 新生物形成の検出方法 | |
| KR20200007500A (ko) | 유방암 진단 또는 예후 예측용 마커 및 이의 용도 | |
| JP4344165B2 (ja) | ケロイドの診断方法 | |
| JP2002526760A (ja) | 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法 | |
| US6858386B1 (en) | Method of diagnosing, monitoring, staging, imaging and treating colon cancer | |
| JPH09262100A (ja) | テロメラーゼ活性の存在を測定することによる尿試料中のヒト膀胱癌細胞の検出方法 | |
| JP2004511758A (ja) | 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法 | |
| JP2002526752A (ja) | 婦人科がんおよび前立腺がんの診断、モニタリング、病期分類および治療の新規方法 | |
| HK1086331B (en) | Compounds and methods for detection of carcinomas and their precursor lesions | |
| HK1086331A1 (zh) | 用於检测癌症及其前体病变的化合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050906 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080421 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080717 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080725 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080818 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090819 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100819 |